HOPE for Human Extended Criteria and Donation After Brain Death Donor (ECD-DBD) Liver Allografts

Liver Transplant Clinical Trial

— HOPE-ECD-DBD  

Official title:

Hypothermic Oxygenated Machine Perfusion (HOPE) for Liver Transplantation of Human Liver Allografts From Extended Criteria Donors (ECD) in Donation After Brain Death (DBD); a Multicenter Randomized Controlled Trial (HOPE ECD-DBD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03124641
• Other study ID #: EK 049/17
• Status: Completed
• Phase: N/A
• Start date: January 17, 2017
• Est. completion date: September 30, 2020

Study information

• Verified date: January 2021
• Source: University Hospital, Aachen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test the effects of hypothermic oxygenated machine perfusion (HOPE) in a phase-II prospective multicenter randomized clinical trial (RCT) on extended criteria donor allografts (ECD) in donation after brain death (DBD) orthotropic liver-transplantation (OLT) (HOPE-ECD-DBD). Human whole organ liver grafts will be submitted to 1-2 hours of HOPE via the portal vein directly before implantation and going to be compared to a control-group of patients transplanted after conventional cold storage (CCS). Primary (early graft injury) and secondary (e.g. postoperative complications, hospital stay, survival) objectives are going to be analysed in a 12 month follow up. Ischemia-reperfusion (I/R) injury and inflammation will be assessed using liver tissue, serum and bile samples as well as machine perfusion perfusate.

To improve the availability of donor allografts and reduce waiting list mortality, graft acceptance criteria were extended increasingly over the decades. The use of extended criteria donor (ECD) allografts is associated with higher incidences of primary graft non-function (PNF) and/or delayed graft function (DGF). As such, several strategies have been developed aiming at "reconditioning" poor quality ECD grafts. HOPE has been tested intensively in pre-clinical animal experiments. Although, its known that HOPE can exert its reconditioning effect via cellular and mitochondrial pathways in the endothelial and parenchymal cells, there is still scarce evidence available on the exact subcellular mechanism of HOPE induced organ protection in the clinical scenario of liver transplantation. In donation after cardiac death (DCD) OLT, the positive effects of HOPE have been shown to reduce the incidence of biliary complications, mitochondrial damage and improve the overall cellular energy-status.

In the HOPE setting, organ perfusion is performed in the transplant center shortly before the actual implantation with oxygenated perfusate using an extra corporal organ perfusion system. The first clinical study with this promising technique was recently reported in a Swiss cohort of patients who received DCD allografts. In organ donation after brain death (DBD), the only legally accepted approach for organ donation in most countries, HOPE and its effect on early graft injury and postoperative complications remains to be elucidated.

Description:

The present RCT comprises two groups, a perfusion (group 1; HOPE) and a control conventional cold storage (group 2; CCS) group. Patients with proven written informed consent on waiting list for orthotopic liver transplantation will be recruited. Randomization is performed with an online randomizing tool for clinical trials (www.randomizer.at) at the time of allograft arrival at the transplant center and acceptance of the organ for transplantation. Stratified randomization model will be used to ensure balance of prognostic variables between the treatment groups.

In case of randomisation to group 1, HOPE will be applied to the allograft in the operation room, directly after the back table preparation. The application of HOPE to the liver allograft will not delay the implantation due to the fact that it is performed parallel to the recipient hepatectomy.

Commercially available and machine-perfusion approved Belzer MPS® UW solution (Belzer Organ Preservation Solutions, Bridge for Life) will be used as perfusate for machine perfusion.

Patients will be followed for one year after OLT.

Interim analysis: After n=12 per randomized group is reached, data will be analyzed by an independent Data Monitoring Committee. The RCT will be stopped if one of the following criteria is reached:

Significantly higher serum ALT levels (p<0.001 using Student's t-test) in the HOPE group compared to the CCS group (Efficacy).

The proportion of Grade ≥ III complications is significantly higher (p<0.05, Fischer's exact test) in the HOPE group when compared to the CCS group (Safety).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: September 30, 2020
• Est. primary completion date: September 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

-Patients with signed informed consent, suffering from end stage-liver disease and/or malignant liver tumors listed for liver transplantation and receiving ECD organs.

ECD Criteria are defined as:

• Donors 65 years of age and older

• Intensive therapy of the donor was required before donation for at least 7 days, --Obesity of the donor with a Body Mass Index > 30

• Fatty liver (with histology) > 40 %

• Serum-Sodium > 165 mmol/l

• Serum AST or ALT > 3 x normal, Serum-Bilirubin > 2 mg/dl)

Exclusion Criteria:

• Recipients of split of living donor liver transplants

• Previous liver transplantation

• Combined transplantations (liver-kidney, liver-lung, etc.)

• Participation in other liver related trials

• The subject received an investigational drug within 30 days prior to inclusion

• The subject is unwilling or unable to follow the procedures outlined in the protocol

• The subject is mentally or legally incapacitated

• Patient is not able to understand the procedures due to language barriers

• Family members of the investigators or employees of the participating department

Related Conditions & MeSH terms

• Brain Death
• Hepatocellular Injury
• Liver Transplant

Intervention

Device:
• Hypothermic oxygenated perfusion (HOPE)
HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa

Procedure:
• Conventional cold storage (CCS)
Conventional static cold storage (CCS) on temperature 4-6 °C from organ procurement

Locations

Country	Name	City	State
Czechia	Department of Transplantation Surgery, Institute for Clinical and Experimental Medicine	Prague
Germany	Department of Surgery and Transplantation, University Hospital RWTH Aachen	Aachen
Germany	Department of Surgery, Campus Charité Mitte | Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Germany	Berlin
Germany	Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich	Munich

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Aachen

Countries where clinical trial is conducted

Czechia,  Germany, 

References & Publications (1)

Czigany Z, Schöning W, Ulmer TF, Bednarsch J, Amygdalos I, Cramer T, Rogiers X, Popescu I, Botea F, Fronek J, Kroy D, Koch A, Tacke F, Trautwein C, Tolba RH, Hein M, Koek GH, Dejong CHC, Neumann UP, Lurje G. Hypothermic oxygenated machine perfusion (HOPE) for orthotopic liver transplantation of human liver allografts from extended criteria donors (ECD) in donation after brain death (DBD): a prospective multicentre randomised controlled trial (HOPE ECD-DBD). BMJ Open. 2017 Oct 10;7(10):e017558. doi: 10.1136/bmjopen-2017-017558. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Early graft injury	Peak serum alanine aminotransferase-ALT	During the first week postoperatively (absolute and relative delta)
Secondary	Postoperative complications	Clavien-Dindo complication score	Subjects will be followed for one year postoperatively
Secondary	Cumulative postoperative complications	Comprehensive complication index (CCI)	Subjects will be followed for one year postoperatively
Secondary	Early allograft dysfunction (EAD)	Olthoff criteria (bilirubin 10mg/dL on day 7, international normalized ratio 1.6 on day 7, and alanine or aspartate aminotransferases >2000 IU/L)	During the first week postoperatively
Secondary	Duration of intensive care stay	Duration of ICU stay	Subjects will be followed for one year postoperatively
Secondary	Duration of hospital stay	Duration of hospitalisation	Subjects will be followed for one year postoperatively
Secondary	One-year recipient- and graft survival	One year patient and graft survival	Subjects will be followed for one year postoperatively
Secondary	Ischemia-reperfusion injury and inflammatory responses	Liver samples taken upon arrival of the organ (before HOPE or corresponding cold-storage), and at the end of the implantation procedure before closure of the abdomen	Before preservation (HOPE or CCS), after liver implantation (0-3 hrs)
Secondary	(in selected centers) Biliary epithelial cell injury	Bile samples collected from T-Drain	Postoperative days 1, 2, and 3

External Links

•   HOPE ECD-DBD webpage